JP2011519941A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011519941A5 JP2011519941A5 JP2011508584A JP2011508584A JP2011519941A5 JP 2011519941 A5 JP2011519941 A5 JP 2011519941A5 JP 2011508584 A JP2011508584 A JP 2011508584A JP 2011508584 A JP2011508584 A JP 2011508584A JP 2011519941 A5 JP2011519941 A5 JP 2011519941A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- compound
- formula
- cancer
- erbb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 102000056372 ErbB-3 Receptor Human genes 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 150000004682 monohydrates Chemical class 0.000 claims 1
- -1 morpholino, piperidinyl Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N COCCOc1cc2c(Nc3cccc(C#C)c3)ncnc2cc1OCCOC Chemical compound COCCOc1cc2c(Nc3cccc(C#C)c3)ncnc2cc1OCCOC AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5032208P | 2008-05-05 | 2008-05-05 | |
| US61/050,322 | 2008-05-05 | ||
| PCT/US2009/042768 WO2009137429A1 (en) | 2008-05-05 | 2009-05-05 | Method of treating cancer using a cmet and axl inhibitor and an erbb inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011519941A JP2011519941A (ja) | 2011-07-14 |
| JP2011519941A5 true JP2011519941A5 (enExample) | 2012-06-21 |
Family
ID=41257222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011508584A Pending JP2011519941A (ja) | 2008-05-05 | 2009-05-05 | ｃＭＥＴおよびＡＸＬの阻害剤並びにＥｒｂＢ阻害剤を使用するガンの治療方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20090274693A1 (enExample) |
| EP (1) | EP2274304A4 (enExample) |
| JP (1) | JP2011519941A (enExample) |
| KR (1) | KR20110004462A (enExample) |
| CN (1) | CN102083824A (enExample) |
| AR (1) | AR071631A1 (enExample) |
| AU (1) | AU2009244453B2 (enExample) |
| BR (1) | BRPI0912582A2 (enExample) |
| CA (1) | CA2723699A1 (enExample) |
| CL (1) | CL2009001063A1 (enExample) |
| EA (1) | EA020779B1 (enExample) |
| IL (1) | IL209057A0 (enExample) |
| MX (1) | MX2010012101A (enExample) |
| PE (1) | PE20091832A1 (enExample) |
| SG (1) | SG190623A1 (enExample) |
| TW (1) | TW201006829A (enExample) |
| UY (1) | UY31800A (enExample) |
| WO (1) | WO2009137429A1 (enExample) |
| ZA (1) | ZA201007722B (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3173084B1 (en) | 2005-11-11 | 2019-10-23 | Boehringer Ingelheim International GmbH | Quinazoline derivatives for the treatment of cancer diseases |
| CA2758030C (en) | 2009-01-16 | 2019-01-08 | Exelixis, Inc. | Malate salt of n-(4-{[6,7-bis(methyloxy)quin0lin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| SG174904A1 (en) | 2009-03-25 | 2011-11-28 | Genentech Inc | Anti-fgfr3 antibodies and methods using same |
| HRP20191005T1 (hr) | 2009-07-06 | 2019-08-23 | Boehringer Ingelheim International Gmbh | Postupak sušenja bibw2992, njegovih soli i čvrstih farmaceutskih formulacija koje sadrže taj djelatni sastojak |
| AR077595A1 (es) * | 2009-07-27 | 2011-09-07 | Genentech Inc | Tratamientos de combinacion |
| WO2011014872A2 (en) * | 2009-07-31 | 2011-02-03 | The Johns Hopkins University | Compositions and methods for diagnosing, treating or preventing neoplasias |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| KR101806323B1 (ko) * | 2009-11-13 | 2017-12-07 | 다이이치 산쿄 유럽 게엠베하 | Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법 |
| TWI619495B (zh) | 2010-07-16 | 2018-04-01 | 艾克塞里克斯公司 | Ｃ-ｍｅｔ調節劑醫藥組合物 |
| ME02637B (me) | 2010-08-20 | 2017-06-20 | Novartis Ag | Antitela za receptor 3 faktora rasta epiderma (her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| EP2621481B2 (en) | 2010-09-27 | 2022-10-19 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases |
| MX2013007429A (es) * | 2010-12-23 | 2014-01-31 | Nestec Sa | Seleccion de farmacos para terapia de cancer maligno usando disposiciones a base de anticuerpos. |
| CN102532109B (zh) * | 2010-12-27 | 2015-05-13 | 浙江海正药业股份有限公司 | 一种拉帕替尼及其盐的合成方法 |
| CN102093421B (zh) * | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| CA2826751C (en) | 2011-02-10 | 2021-05-18 | Exelixis, Inc. | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| MX2013012695A (es) * | 2011-05-02 | 2014-03-27 | Exelixis Inc | Metodo para el tratamiento del cancer y el dolor por cancer de hueso. |
| KR20140069133A (ko) | 2011-09-22 | 2014-06-09 | 엑셀리시스, 인코포레이티드 | 골다공증의 치료방법 |
| EP2768796B1 (en) | 2011-10-20 | 2019-11-20 | Exelixis, Inc. | Process for preparing quinoline derivatives |
| EA023521B1 (ru) | 2011-11-14 | 2016-06-30 | Сефалон, Инк. | ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ |
| ES2758433T3 (es) * | 2011-12-05 | 2020-05-05 | Novartis Ag | Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3) |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| AU2013216006B2 (en) | 2012-01-31 | 2017-06-08 | Daiichi Sankyo Company, Limited | Pyridone derivatives |
| WO2013166296A1 (en) | 2012-05-02 | 2013-11-07 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
| CN103664879A (zh) * | 2012-09-17 | 2014-03-26 | 杨育新 | 一类治疗创伤性脑损伤疾病的化合物及其用途 |
| CN103705521A (zh) * | 2012-09-28 | 2014-04-09 | 韩冰 | 一类治疗脑梗塞的化合物及其用途 |
| WO2014093750A1 (en) * | 2012-12-14 | 2014-06-19 | Glaxosmithkline Llc | Method of administration and treatment |
| BR112015023109A2 (pt) | 2013-03-15 | 2018-05-15 | Exelixis Inc | Metabolitos de n-(4-{[6,7-bis(metiloxi)quinoloin-4-il] oxi}fenil)-n -(4-fluorofenil)ciclopropano-1, 1- dicarboxamida |
| KR102060540B1 (ko) | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
| WO2014165786A1 (en) | 2013-04-04 | 2014-10-09 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
| TWI649308B (zh) * | 2013-07-24 | 2019-02-01 | 小野藥品工業股份有限公司 | 喹啉衍生物 |
| EP3057608B1 (en) * | 2013-10-14 | 2025-12-10 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type iii domain binding molecules |
| EP3103453B1 (en) * | 2014-02-04 | 2020-04-01 | Astellas Pharma Inc. | Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient |
| CA2939546C (en) | 2014-02-14 | 2023-01-17 | Exelixis, Inc. | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| EA201691850A1 (ru) | 2014-03-17 | 2016-12-30 | Экселиксис, Инк. | Дозирование составов, содержащих кабозантиниб |
| SG11201608189WA (en) * | 2014-04-03 | 2016-10-28 | Merck Patent Gmbh | Combinations of cancer therapeutics |
| KR102223502B1 (ko) | 2014-05-09 | 2021-03-05 | 삼성전자주식회사 | 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용 |
| TWI723572B (zh) | 2014-07-07 | 2021-04-01 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
| MA40386A (fr) | 2014-07-31 | 2016-02-04 | Exelixis Inc | Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci |
| BR112017002318A2 (pt) | 2014-08-05 | 2018-07-17 | Exelixis, Inc. | combinações de fármacos para tratar mieloma múltiplo. |
| ES2749726T3 (es) | 2014-12-25 | 2020-03-23 | Ono Pharmaceutical Co | Derivado de quinolina |
| FR3039401B1 (fr) * | 2015-07-31 | 2018-07-13 | Les Laboratoires Servier | Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr |
| CN106467541B (zh) * | 2015-08-18 | 2019-04-05 | 暨南大学 | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 |
| CN109069499A (zh) | 2016-04-15 | 2018-12-21 | 埃克塞里艾克西斯公司 | 使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法 |
| WO2017223180A2 (en) | 2016-06-21 | 2017-12-28 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type iii domain binding molecules |
| CN110437145A (zh) * | 2016-09-13 | 2019-11-12 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| CN107235897B (zh) * | 2016-09-27 | 2019-08-16 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| EP3554535A4 (en) | 2016-12-14 | 2020-10-21 | Janssen Biotech, Inc. | PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS |
| EP3554561B1 (en) | 2016-12-14 | 2023-06-28 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| RU2759952C2 (ru) | 2016-12-14 | 2021-11-19 | Янссен Байотек, Инк. | Cd8a-связывающие домены типа iii фибронектина |
| MY196680A (en) | 2017-01-26 | 2023-04-29 | Ono Pharmaceutical Co | Ethanesulfonate salt of n-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2- pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3- quinolinecarboxamide |
| ES2991062T3 (es) | 2017-02-15 | 2024-12-02 | Taiho Pharmaceutical Co Ltd | Composición farmacéutica |
| US12280045B2 (en) | 2017-09-08 | 2025-04-22 | Taiho Pharmaceutical Co., Ltd. | Antitumor agent and antitumor effect potentiator |
| JP7223998B2 (ja) | 2017-10-13 | 2023-02-17 | 小野薬品工業株式会社 | Ａｘｌ阻害剤を有効成分として含む固形がん治療剤 |
| TWI770624B (zh) | 2018-06-15 | 2022-07-11 | 漢達生技醫藥股份有限公司 | 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途 |
| CA3126721A1 (en) * | 2019-01-25 | 2020-07-30 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| US11628222B2 (en) | 2019-10-14 | 2023-04-18 | Aro Biotherapeutics Company | CD71 binding fibronectin type III domains |
| US12491255B2 (en) | 2019-10-14 | 2025-12-09 | Aro Biotherapeutics Company | EPCAM binding fibronectin type III domains |
| CN115073367A (zh) * | 2021-03-16 | 2022-09-20 | 南京科默生物医药有限公司 | 一种用作axl抑制剂的抗肿瘤化合物及其用途 |
| CA3214552A1 (en) | 2021-04-14 | 2022-10-20 | Russell C. Addis | Cd71 binding fibronectin type iii domains |
| CA3215367A1 (en) | 2021-04-14 | 2022-10-20 | Swapnil Kulkarni | Fn3 domain-sirna conjugates and uses thereof |
| AU2024215796A1 (en) | 2023-01-31 | 2025-05-15 | Handa Oncology, Llc | Improved cabozantinib compositions and methods of use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60203260T2 (de) * | 2001-01-16 | 2006-02-02 | Glaxo Group Ltd., Greenford | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs |
| ES2651730T3 (es) * | 2003-09-26 | 2018-01-29 | Exelixis, Inc. | Moduladores c-Met y métodos de uso |
| ITRM20030475A1 (it) * | 2003-10-15 | 2005-04-16 | Sipa Societa Industrializzazione P Rogettazione E | Impianto e metodo per il condizionamento termico di oggetti |
| UA96139C2 (uk) * | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
| US20090123474A1 (en) * | 2005-12-15 | 2009-05-14 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer |
| WO2007081978A2 (en) * | 2006-01-11 | 2007-07-19 | Angion Biomedica Corporation | Modulators of hepatocyte growth factor / c-met activity |
| WO2008076415A1 (en) * | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
| ES2529790T3 (es) * | 2007-04-13 | 2015-02-25 | Dana-Farber Cancer Institute, Inc. | Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB |
| CN101743253B (zh) * | 2007-05-17 | 2013-05-08 | 健泰科生物技术公司 | 神经毡蛋白片段与神经毡蛋白抗体复合物的晶体结构 |
| WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| JP5688840B2 (ja) * | 2007-09-10 | 2015-03-25 | ボストン バイオメディカル， インコーポレイテッド | 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤 |
-
2009
- 2009-04-30 UY UY0001031800A patent/UY31800A/es not_active Application Discontinuation
- 2009-05-04 CL CL2009001063A patent/CL2009001063A1/es unknown
- 2009-05-04 PE PE2009000602A patent/PE20091832A1/es not_active Application Discontinuation
- 2009-05-04 TW TW098114669A patent/TW201006829A/zh unknown
- 2009-05-05 AR ARP090101611A patent/AR071631A1/es unknown
- 2009-05-05 EP EP09743415A patent/EP2274304A4/en not_active Withdrawn
- 2009-05-05 US US12/435,473 patent/US20090274693A1/en not_active Abandoned
- 2009-05-05 EA EA201071268A patent/EA020779B1/ru not_active IP Right Cessation
- 2009-05-05 BR BRPI0912582-5A patent/BRPI0912582A2/pt not_active IP Right Cessation
- 2009-05-05 CA CA2723699A patent/CA2723699A1/en not_active Abandoned
- 2009-05-05 KR KR1020107027183A patent/KR20110004462A/ko not_active Ceased
- 2009-05-05 MX MX2010012101A patent/MX2010012101A/es not_active Application Discontinuation
- 2009-05-05 CN CN2009801261595A patent/CN102083824A/zh active Pending
- 2009-05-05 WO PCT/US2009/042768 patent/WO2009137429A1/en not_active Ceased
- 2009-05-05 SG SG2013033709A patent/SG190623A1/en unknown
- 2009-05-05 JP JP2011508584A patent/JP2011519941A/ja active Pending
- 2009-05-05 AU AU2009244453A patent/AU2009244453B2/en not_active Ceased
-
2010
- 2010-10-28 ZA ZA2010/07722A patent/ZA201007722B/en unknown
- 2010-11-01 IL IL209057A patent/IL209057A0/en unknown
-
2013
- 2013-01-29 US US13/753,031 patent/US20130142790A1/en not_active Abandoned
- 2013-01-29 US US13/753,146 patent/US20130150363A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011519941A5 (enExample) | ||
| AR071631A1 (es) | Uso de un compuesto de quinilinil -4-oxi- fenil- ciclopropildicarboxamida y un inhibidor de erbb para preparar un medicamento util para el tratamiento de canceres | |
| RU2013143381A (ru) | Фармацевтически приемлемая соль (е)-n-[4-[[3-хлор-4-(2-пиридилметокси)фенил]амино]-3-циано-7-этокси-6-хинолил]3-[(2r)-1-метилпирролидин-2-ил]проп-2-енамида, способ ее получения и ее медицинское применение | |
| JP6557744B2 (ja) | 抗腫瘍剤及び抗腫瘍効果増強剤 | |
| JP2009507909A5 (enExample) | ||
| JP2012504628A5 (enExample) | ||
| RU2018103454A (ru) | Соединения бензоксазепиноксазолидинонов и способы применения | |
| JP2018504418A5 (enExample) | ||
| JP2008535902A5 (enExample) | ||
| JP2014528433A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP2013510120A5 (enExample) | ||
| JP2014533284A5 (enExample) | ||
| JP2016053042A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| JP2017510661A5 (enExample) | ||
| JP2015536986A5 (enExample) | ||
| JP2013520431A5 (enExample) | ||
| RU2012139825A (ru) | Антагонисты неурегулина и применение их в лечении злокачественного новообразования | |
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| JP2014528464A5 (enExample) | ||
| JP2012520321A5 (enExample) | ||
| JP2020534300A5 (enExample) | ||
| JP2014502599A5 (enExample) | ||
| JP2016508135A5 (enExample) |